<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03115255</url>
  </required_header>
  <id_info>
    <org_study_id>XH-17-004</org_study_id>
    <nct_id>NCT03115255</nct_id>
  </id_info>
  <brief_title>Serum Vascular Endothelial Growth Factor in Infants With Intravitreal Ranibizumab</brief_title>
  <official_title>Serum Concentrations of Vascular Endothelial Growth Factor in Infants Treated With Ranibizumab for Retinopathy of Prematurity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the serum concentrations of ranibizumab and vascular endothelial growth factor
      (VEGF) in infants with retinopathy of prematurity (ROP) who received intravitreal ranibizumab
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infants with ROP are studied. They received 0.25 mg or 0.5 mg of intravitreal ranibizumab to
      either 1 eye (unilateral cases) or both eyes (bilateral cases) with vascularly active ROP.
      Serum samples are collected 1 day before and 1 day, 3 days, 1 week after intravitreal
      ranibizumab. The serum concentrations of ranibizumab and VEGF are measured by enzyme-linked
      immunosorbent assay, and the changes of the serum VEGF levels are determined.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effect of intravitreal ranibizumab on serum VEGF level</measure>
    <time_frame>1 day before and 1 day, 3 days, 1 week after intravitreal ranibizumab</time_frame>
    <description>the changes of the serum VEGF levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The effect of intravitreal ranibizumab on weight</measure>
    <time_frame>corrected age of six month</time_frame>
    <description>measure weight of the infants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of intravitreal ranibizumab on height</measure>
    <time_frame>corrected age of six month</time_frame>
    <description>measure height of the infants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of intravitreal ranibizumab on neurologic development</measure>
    <time_frame>corrected age of six month</time_frame>
    <description>Gesell development diagnosis scale</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Infant, Premature, Diseases</condition>
  <arm_group>
    <arm_group_label>serum VEGF level</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Serum samples are collected 1 day before and 1 day, 3 days, 1 week after intravitreal ranibizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravitreal ranibizumab</intervention_name>
    <description>0.25 mg intravitreal ranibizumab to either 1 eye (unilateral cases) or both eyes (bilateral cases)</description>
    <arm_group_label>serum VEGF level</arm_group_label>
    <other_name>lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infants with vascularly active ROP

          -  intravitreal ranibizumab

        Exclusion Criteria:

          -  already accepted laser therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongping Xia, MD. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hongping Xia, MD. PhD.</last_name>
    <phone>86-25078999</phone>
    <phone_ext>8320</phone_ext>
    <email>xiahp@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xinhua Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongping Xia, M.D.</last_name>
      <phone>+86-13641769263</phone>
      <email>xiahp@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2017</study_first_submitted>
  <study_first_submitted_qc>April 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>retinopathy of prematurity</keyword>
  <keyword>ranibizumab</keyword>
  <keyword>vascular endothelial growth factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinopathy of Prematurity</mesh_term>
    <mesh_term>Infant, Premature, Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

